Drug Name | Pathway ID | Pathway name | P-value | No. of gene members | UniProt AC | Gene name | Detail of Coexpression | |
---|
Clozapine | hsa00030 | Pentose phosphate pathway | 3.06E-04 | 3 | P60891, P51854, P37837 | PRPS1, TKTL1, TALDO1 | More | | Clozapine | hsa00040 | Pentose and glucuronate interconversions | 2.33E-04 | 2 | P15121, P14550 | AKR1B1, AKR1A1 | More | | Clozapine | hsa00051 | Fructose and mannose metabolism | 4.00E-02 | 2 | P60174, P04075 | TPI1, ALDOA | More | | Clozapine | hsa00190 | Oxidative phosphorylation | 2.29E-02 | 2 | Q16718, O14521 | NDUFA5, SDHD | More | | Clozapine | hsa00220 | Arginine biosynthesis | 3.83E-02 | 2 | P05089, P49448 | ARG1, GLUD2 | More | | Clozapine | hsa00500 | Starch and sucrose metabolism | 1.47E-02 | 3 | O43451, P46976, P06737 | MGAM, GYG1, PYGL | More | | Clozapine | hsa00510 | N-Glycan biosynthesis | 3.15E-02 | 2 | P15907, Q9NR34 | ST6GAL1, MAN1C1 | More | | Clozapine | hsa00561 | Glycerolipid metabolism | 2.62E-02 | 2 | P15121, P14550 | AKR1B1, AKR1A1 | More | | Clozapine | hsa00590 | Arachidonic acid metabolism | 3.85E-02 | 2 | P11712, P09960 | CYP2C9, LTA4H | More | | Clozapine | hsa00591 | Linoleic acid metabolism | 4.07E-02 | 1 | P11712 | CYP2C9 | More | | Clozapine | hsa00730 | Thiamine metabolism | 2.70E-03 | 2 | P05186, P24666 | ALPL, ACP1 | More | | Clozapine | hsa00770 | Pantothenate and CoA biosynthesis | 1.15E-02 | 2 | O95498, Q9NRN7 | VNN2, AASDHPPT | More | | Clozapine | hsa00790 | Folate biosynthesis | 2.02E-02 | 1 | P15121 | AKR1B1 | More | | Clozapine | hsa00830 | Retinol metabolism | 3.93E-02 | 3 | P00352, Q9BPW9, O75911 | ALDH1A1, DHRS9, DHRS3 | More | | Clozapine | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 6.38E-04 | 3 | P78417, P09211, P11712 | GSTO1, GSTP1, CYP2C9 | More | | Clozapine | hsa00982 | Drug metabolism - cytochrome P450 | 9.14E-03 | 2 | P11712, P78417 | CYP2C9, GSTO1 | More | | Clozapine | hsa00983 | Drug metabolism - other enzymes | 1.63E-02 | 2 | P20839, Q16772 | IMPDH1, GSTA3 | More | | Clozapine | hsa01100 | Metabolic pathways | 6.45E-03 | 34 | Q9NR34, P35790, P05089, Q16772, P30041, P32320, P20839, P22748, P55809, P06280, O94777, Q16875, O43286, O43451, P05186, P24666, P15121, O95861, P14550, Q9HCC0, P33121, Q9UHK6, Q86VZ5, P57054, Q9UNP4, Q9BX95, P32321, Q9BPW9, O75911, Q9UHY7, P43490, P46976, P06737, Q9NVH6 | MAN1C1, CHKA, ARG1, GSTA3, PRDX6, CDA, IMPDH1, CA4, OXCT1, GLA, DPM2, PFKFB3, B4GALT5, MGAM, ALPL, ACP1, AKR1B1, BPNT1, AKR1A1, MCCC2, ACSL1, AMACR, SGMS1, PIGP, ST3GAL5, SGPP1, DCTD, DHRS9, DHRS3, ENOPH1, PBEF1, GYG1, PYGL, TMLHE | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | Q9NR34 | MAN1C1 | Mannosyl-oligosaccharide 1,2-alpha-mannosidase IC | -0.716 | Q16772 | GSTA3 | Glutathione S-transferase A3 | P35790 | CHKA | Choline kinase alpha | 0.74 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | P05089 | ARG1 | Arginase-1 | 0.702 | Q16772 | GSTA3 | Glutathione S-transferase A3 | Q16772 | GSTA3 | Glutathione S-transferase A3 | 1 | Q16772 | GSTA3 | Glutathione S-transferase A3 | P30041 | PRDX6 | Peroxiredoxin-6 | -0.788 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | P32320 | CDA | Cytidine deaminase | 0.701 | Q16772 | GSTA3 | Glutathione S-transferase A3 | P20839 | IMPDH1 | Inosine-5'-monophosphate dehydrogenase 1 | -0.768 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | P22748 | CA4 | Carbonic anhydrase 4 | 0.767 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | P55809 | OXCT1 | Succinyl-CoA:3-ketoacid coenzyme A transferase 1, mitochondrial | -0.746 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | P06280 | GLA | Alpha-galactosidase A | 0.714 | Q16772 | GSTA3 | Glutathione S-transferase A3 | O94777 | DPM2 | Dolichol phosphate-mannose biosynthesis regulatory protein | -0.723 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | Q16875 | PFKFB3 | 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 | 0.849 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | O43286 | B4GALT5 | Beta-1,4-galactosyltransferase 5 | 0.917 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | O43451 | MGAM | Maltase-glucoamylase | 0.871 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | P05186 | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | 0.901 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | P24666 | ACP1 | Low molecular weight phosphotyrosine protein phosphatase | -0.832 | Q16772 | GSTA3 | Glutathione S-transferase A3 | P15121 | AKR1B1 | Aldo-keto reductase family 1 member B1 | -0.793 | Q16772 | GSTA3 | Glutathione S-transferase A3 | O95861 | BPNT1 | 3'(2'),5'-bisphosphate nucleotidase 1 | 0.7 | Q16772 | GSTA3 | Glutathione S-transferase A3 | P14550 | AKR1A1 | Aldo-keto reductase family 1 member A1 | -0.706 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | Q9HCC0 | MCCC2 | Methylcrotonoyl-CoA carboxylase beta chain, mitochondrial | -0.782 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | P33121 | ACSL1 | Long-chain-fatty-acid--CoA ligase 1 | 0.886 | Q16772 | GSTA3 | Glutathione S-transferase A3 | Q9UHK6 | AMACR | Alpha-methylacyl-CoA racemase | 0.787 | Q16772 | GSTA3 | Glutathione S-transferase A3 | Q86VZ5 | SGMS1 | Phosphatidylcholine:ceramide cholinephosphotransferase 1 | 0.907 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | P57054 | PIGP | Phosphatidylinositol N-acetylglucosaminyltransferase subunit P | -0.881 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | Q9UNP4 | ST3GAL5 | Lactosylceramide alpha-2,3-sialyltransferase | -0.819 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | Q9BX95 | SGPP1 | Sphingosine-1-phosphate phosphatase 1 | -0.743 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | P32321 | DCTD | Deoxycytidylate deaminase | -0.748 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | Q9BPW9 | DHRS9 | Dehydrogenase/reductase SDR family member 9 | 0.817 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | O75911 | DHRS3 | Short-chain dehydrogenase/reductase 3 | -0.81 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | Q9UHY7 | ENOPH1 | Enolase-phosphatase E1 | -0.737 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | 0.883 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | P46976 | GYG1 | Glycogenin-1 | 0.817 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | P06737 | PYGL | Glycogen phosphorylase, liver form | 0.863 | Q16772 | GSTA3 | Glutathione S-transferase A3 | Q9NVH6 | TMLHE | Trimethyllysine dioxygenase, mitochondrial | 0.736 |
| Clozapine | hsa01200 | Carbon metabolism | 4.32E-02 | 3 | P51854, P37837, P60891 | TKTL1, TALDO1, PRPS1 | More | | Clozapine | hsa01230 | Biosynthesis of amino acids | 2.60E-02 | 3 | P51854, P60891, P37837 | TKTL1, PRPS1, TALDO1 | More | | Clozapine | hsa01523 | Antifolate resistance | 1.68E-02 | 2 | Q92820, P04818 | GGH, TYMS | More | | Clozapine | hsa02010 | ABC transporters | 2.29E-02 | 2 | P45844, P08183 | ABCG1, ABCB1 | More | | Clozapine | hsa03010 | Ribosome | 1.13E-06 | 12 | P26373, P42677, P40429, P62917, P46776, Q9H0U6, Q07020, Q02878, P27635, P05386, P62249, P23396 | RPL13, RPS27, RPL13A, RPL8, RPL27A, MRPL18, RPL18, RPL6, RPL10, RPLP1, RPS16, RPS3 | More | | Clozapine | hsa03020 | RNA polymerase | 1.81E-02 | 1 | P24928 | POLR2A | More | | Clozapine | hsa03022 | Basal transcription factors | 3.32E-02 | 2 | O00268, Q15544 | TAF4, TAF11 | More | | Clozapine | hsa03040 | Spliceosome | 3.17E-02 | 6 | Q14562, O43143, Q07955, Q13243, P11142, O75643 | DHX8, DHX15, SFRS1, SFRS5, HSPA8, ASCC3L1 | More | | Clozapine | hsa03050 | Proteasome | 1.21E-02 | 1 | P28074 | PSMB5 | More | | Clozapine | hsa04012 | ErbB signaling pathway | 1.72E-02 | 4 | Q13153, P16333, P19174, P01106 | PAK1, NCK1, PLCG1, MYC | More | | Clozapine | hsa04024 | cAMP signaling pathway | 4.80E-02 | 1 | Q13153 | PAK1 | More | | Clozapine | hsa04060 | Cytokine-cytokine receptor interaction | 5.34E-03 | 11 | P14784, P27930, P14778, P26842, Q06643, Q13651, P25024, Q9UBD3, P47992, P09341, P01730 | IL2RB, IL1R2, IL1R1, CD27, LTB, IL10RA, CXCR1, XCL2, XCL1, CXCL1, CD4 | More | | Clozapine | hsa04061 | Viral protein interaction with cytokine and cytokine receptor | 9.53E-04 | 7 | P09341, P25024, P02775, P47992, Q9UBD3, Q13651, P14784 | CXCL1, CXCR1, PPBP, XCL1, XCL2, IL10RA, IL2RB | More | | Clozapine | hsa04062 | Chemokine signaling pathway | 6.73E-03 | 9 | P25024, P09341, P47992, Q9UBD3, P07948, P63218, P50151, P43250, Q08881 | CXCR1, CXCL1, XCL1, XCL2, LYN, GNG5, GNG10, GRK6, ITK | More | | Clozapine | hsa04064 | NF-kappa B signaling pathway | 7.57E-06 | 15 | P10415, O00463, P14778, P01375, Q04759, Q9UDY8, Q13077, Q16548, P07948, P06239, Q8WV28, Q13315, P24522, P09341, Q06643 | BCL2, TRAF5, IL1R1, TNF, PRKCQ, MALT1, TRAF1, BCL2A1, LYN, LCK, BLNK, ATM, GADD45A, CXCL1, LTB | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | P10415 | BCL2 | Apoptosis regulator Bcl-2 | 0.744 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | O00463 | TRAF5 | TNF receptor-associated factor 5 | -0.837 | P06239 | LCK | Tyrosine-protein kinase Lck | O00463 | TRAF5 | TNF receptor-associated factor 5 | 0.718 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | O00463 | TRAF5 | TNF receptor-associated factor 5 | 0.945 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | P14778 | IL1R1 | Interleukin-1 receptor type 1 | 0.76 | P06239 | LCK | Tyrosine-protein kinase Lck | P14778 | IL1R1 | Interleukin-1 receptor type 1 | -0.782 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | P01375 | TNF | Tumor necrosis factor | -0.79 | P06239 | LCK | Tyrosine-protein kinase Lck | Q04759 | PRKCQ | Protein kinase C theta type | 0.779 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | Q04759 | PRKCQ | Protein kinase C theta type | 0.803 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | Q9UDY8 | MALT1 | Mucosa-associated lymphoid tissue lymphoma translocation protein 1 | 0.721 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | Q13077 | TRAF1 | TNF receptor-associated factor 1 | -0.73 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | Q13077 | TRAF1 | TNF receptor-associated factor 1 | 0.83 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | Q16548 | BCL2A1 | Bcl-2-related protein A1 | 0.875 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | Q16548 | BCL2A1 | Bcl-2-related protein A1 | -0.877 | P06239 | LCK | Tyrosine-protein kinase Lck | P07948 | LYN | Tyrosine-protein kinase Lyn | -0.701 | P06239 | LCK | Tyrosine-protein kinase Lck | P06239 | LCK | Tyrosine-protein kinase Lck | 1 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | P06239 | LCK | Tyrosine-protein kinase Lck | 0.774 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | Q8WV28 | BLNK | B-cell linker protein | -0.816 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | Q13315 | ATM | Serine-protein kinase ATM | 0.752 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | P24522 | GADD45A | Growth arrest and DNA damage-inducible protein GADD45 alpha | 0.796 | P06239 | LCK | Tyrosine-protein kinase Lck | P24522 | GADD45A | Growth arrest and DNA damage-inducible protein GADD45 alpha | -0.724 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | P24522 | GADD45A | Growth arrest and DNA damage-inducible protein GADD45 alpha | -0.75 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | P09341 | CXCL1 | Growth-regulated alpha protein | 0.7 | P06239 | LCK | Tyrosine-protein kinase Lck | P09341 | CXCL1 | Growth-regulated alpha protein | -0.805 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | P09341 | CXCL1 | Growth-regulated alpha protein | -0.802 | P06239 | LCK | Tyrosine-protein kinase Lck | Q06643 | LTB | Lymphotoxin-beta | 0.846 |
| Clozapine | hsa04070 | Phosphatidylinositol signaling system | 2.56E-02 | 4 | P19174, P0DP23, P23743, P27987 | PLCG1, CALM1, DGKA, ITPKB | More | | Clozapine | hsa04071 | Sphingolipid signaling pathway | 1.19E-02 | 4 | P21453, Q9H228, P01375, Q13362 | S1PR1, EDG8, TNF, PPP2R5C | More | | Clozapine | hsa04080 | Neuroactive ligand-receptor interaction | 1.97E-02 | 5 | P28472, P21453, Q9H228, P21730, P07550 | GABRB3, S1PR1, EDG8, C5AR1, ADRB2 | More | | Clozapine | hsa04110 | Cell cycle | 6.63E-04 | 6 | P06493, O60566, P30304, P33981, P42773, P01106 | CDK1, BUB1B, CDC25A, TTK, CDKN2C, MYC | More | | Clozapine | hsa04120 | Ubiquitin mediated proteolysis | 3.44E-02 | 4 | Q14145, Q13042, P62837, Q15751 | KEAP1, CDC16, UBE2D2, HERC1 | More | | Clozapine | hsa04140 | Autophagy - animal | 4.55E-02 | 5 | P22694, Q14643, P10415, Q9H1Y0, Q04759 | PRKACB, ITPR1, BCL2, ATG5, PRKCQ | More | | Clozapine | hsa04141 | Protein processing in endoplasmic reticulum | 3.07E-02 | 5 | P30101, P60604, P11142, P08238, Q9UNL2 | PDIA3, UBE2G2, HSPA8, HSP90AB1, SSR3 | More | | Clozapine | hsa04145 | Phagosome | 3.90E-03 | 7 | O75015, Q15080, P05164, P78380, O60603, P35443, P13765 | FCGR3B, NCF4, MPO, OLR1, TLR2, THBS4, HLA-DOB | More | | Clozapine | hsa04216 | Ferroptosis | 2.75E-02 | 3 | P04637, Q9H1Y0, P33121 | TP53, ATG5, ACSL1 | More | | Clozapine | hsa04217 | Necroptosis | 2.34E-02 | 4 | P01375, P48023, Q14765, Q99878 | TNF, FASLG, STAT4, H2AC14 | More | | Clozapine | hsa04218 | Cellular senescence | 2.35E-02 | 4 | P30281, P01889, P10321, P12236 | CCND3, HLA-B, HLA-C, SLC25A6 | More | | Clozapine | hsa04261 | Adrenergic signaling in cardiomyocytes | 2.95E-02 | 4 | P07550, P22694, P18848, Q13362 | ADRB2, PRKACB, ATF4, PPP2R5C | More | | Clozapine | hsa04371 | Apelin signaling pathway | 1.96E-02 | 5 | P62873, P63218, Q13370, Q14814, P0DP23 | GNB1, GNG5, PDE3B, MEF2D, CALM1 | More | | Clozapine | hsa04392 | Hippo signaling pathway - multiple species | 1.51E-02 | 1 | Q13153 | PAK1 | More | | Clozapine | hsa04530 | Tight junction | 3.29E-02 | 3 | P16989, P56750, Q14247 | CSDA, CLDN17, CTTN | More | | Clozapine | hsa04612 | Antigen processing and presentation | 1.91E-05 | 9 | P13765, P48382, P01730, Q14953, P26715, P26717, Q13241, P01732, P01375 | HLA-DOB, RFX5, CD4, KIR2DS5, KLRC1, KLRC2, KLRD1, CD8A, TNF | More | | Clozapine | hsa04613 | Neutrophil extracellular trap formation | 1.86E-04 | 11 | P19174, P11215, Q13547, P04908, Q93077, P62807, O60814, P68431, P60709, O43315, Q16539 | PLCG1, ITGAM, HDAC1, H2AC4; H2AC8, HIST1H2AC, HIST1H2BC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12, ACTB, AQP9, MAPK14 | More | | Clozapine | hsa04625 | C-type lectin receptor signaling pathway | 3.31E-02 | 1 | Q13153 | PAK1 | More | | Clozapine | hsa04640 | Hematopoietic cell lineage | 1.56E-05 | 13 | P13612, P14778, P27930, P15144, P25063, P07766, P09693, P01732, P01730, P06127, P09564, P13765, P01375 | ITGA4, IL1R1, IL1R2, ANPEP, CD24, CD3E, CD3G, CD8A, CD4, CD5, CD7, HLA-DOB, TNF | More | | Clozapine | hsa04650 | Natural killer cell mediated cytotoxicity | 5.99E-08 | 12 | P01375, P06239, O60880, P20963, Q13153, Q13241, P26718, O14931, O75015, P26717, Q14953, P26715 | TNF, LCK, SH2D1A, CD247, PAK1, KLRD1, KLRK1, NCR3, FCGR3B, KLRC2, KIR2DS5, KLRC1 | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | P01375 | TNF | Tumor necrosis factor | -0.79 | P07550 | ADRB2 | Beta-2 adrenergic receptor | P01375 | TNF | Tumor necrosis factor | -0.755 | P06239 | LCK | Tyrosine-protein kinase Lck | P06239 | LCK | Tyrosine-protein kinase Lck | 1 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | P06239 | LCK | Tyrosine-protein kinase Lck | 0.774 | P06239 | LCK | Tyrosine-protein kinase Lck | O60880 | SH2D1A | SH2 domain-containing protein 1A | 0.906 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | O60880 | SH2D1A | SH2 domain-containing protein 1A | 0.862 | P06239 | LCK | Tyrosine-protein kinase Lck | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.927 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.839 | P07550 | ADRB2 | Beta-2 adrenergic receptor | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.727 | Q13153 | PAK1 | Serine/threonine-protein kinase PAK 1 | Q13153 | PAK1 | Serine/threonine-protein kinase PAK 1 | 1 | P06239 | LCK | Tyrosine-protein kinase Lck | Q13241 | KLRD1 | Natural killer cells antigen CD94 | 0.758 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | Q13241 | KLRD1 | Natural killer cells antigen CD94 | 0.852 | P07550 | ADRB2 | Beta-2 adrenergic receptor | Q13241 | KLRD1 | Natural killer cells antigen CD94 | 0.838 | P06239 | LCK | Tyrosine-protein kinase Lck | P26718 | KLRK1 | NKG2-D type II integral membrane protein | 0.886 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | P26718 | KLRK1 | NKG2-D type II integral membrane protein | 0.922 | P07550 | ADRB2 | Beta-2 adrenergic receptor | P26718 | KLRK1 | NKG2-D type II integral membrane protein | 0.701 | P06239 | LCK | Tyrosine-protein kinase Lck | O14931 | NCR3 | Natural cytotoxicity triggering receptor 3 | 0.732 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | O75015 | FCGR3B | Low affinity immunoglobulin gamma Fc region receptor III-B | -0.778 | P06239 | LCK | Tyrosine-protein kinase Lck | P26717 | KLRC2 | NKG2-C type II integral membrane protein | 0.756 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | P26717 | KLRC2 | NKG2-C type II integral membrane protein | 0.943 | P07550 | ADRB2 | Beta-2 adrenergic receptor | P26717 | KLRC2 | NKG2-C type II integral membrane protein | 0.72 | P07550 | ADRB2 | Beta-2 adrenergic receptor | Q14953 | KIR2DS5 | Killer cell immunoglobulin-like receptor 2DS5 | 0.815 | P06239 | LCK | Tyrosine-protein kinase Lck | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | 0.756 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | 0.943 | P07550 | ADRB2 | Beta-2 adrenergic receptor | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | 0.72 |
| Clozapine | hsa04657 | IL-17 signaling pathway | 4.80E-04 | 9 | O00463, Q16539, P49841, P09341, P19875, P14780, Q9UJX4, P80188, P01375 | TRAF5, MAPK14, GSK3B, CXCL1, CXCL2, MMP9, ANAPC5, LCN2, TNF | More | | Clozapine | hsa04658 | Th1 and Th2 cell differentiation | 1.73E-10 | 14 | Q04759, P07766, P20963, P09693, P19174, P01730, P06239, P42224, Q14765, P23771, Q9UL17, P14784, P13765, Q13761 | PRKCQ, CD3E, CD247, CD3G, PLCG1, CD4, LCK, STAT1, STAT4, GATA3, TBX21, IL2RB, HLA-DOB, RUNX3 | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
P06239 | LCK | Tyrosine-protein kinase Lck | Q04759 | PRKCQ | Protein kinase C theta type | 0.779 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | Q04759 | PRKCQ | Protein kinase C theta type | 0.803 | P07305 | H1-0 | Histone H1.0 | Q04759 | PRKCQ | Protein kinase C theta type | -0.706 | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | P07766 | CD3E | T-cell surface glycoprotein CD3 epsilon chain | 0.805 | P06239 | LCK | Tyrosine-protein kinase Lck | P07766 | CD3E | T-cell surface glycoprotein CD3 epsilon chain | 0.928 | P06239 | LCK | Tyrosine-protein kinase Lck | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.927 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.839 | P06239 | LCK | Tyrosine-protein kinase Lck | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | 0.752 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | 0.813 | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | 1 | P06239 | LCK | Tyrosine-protein kinase Lck | P01730 | CD4 | T-cell surface glycoprotein CD4 | 0.746 | P06239 | LCK | Tyrosine-protein kinase Lck | P06239 | LCK | Tyrosine-protein kinase Lck | 1 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | P06239 | LCK | Tyrosine-protein kinase Lck | 0.774 | P07305 | H1-0 | Histone H1.0 | P06239 | LCK | Tyrosine-protein kinase Lck | -0.716 | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | P42224 | STAT1 | Signal transducer and activator of transcription 1-alpha/beta | 0.851 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | Q14765 | STAT4 | Signal transducer and activator of transcription 4 | 0.904 | P06239 | LCK | Tyrosine-protein kinase Lck | P23771 | GATA3 | Trans-acting T-cell-specific transcription factor GATA-3 | 0.77 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | P23771 | GATA3 | Trans-acting T-cell-specific transcription factor GATA-3 | 0.784 | P07305 | H1-0 | Histone H1.0 | P23771 | GATA3 | Trans-acting T-cell-specific transcription factor GATA-3 | -0.772 | P06239 | LCK | Tyrosine-protein kinase Lck | Q9UL17 | TBX21 | T-box transcription factor TBX21 | 0.866 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | Q9UL17 | TBX21 | T-box transcription factor TBX21 | 0.884 | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | P14784 | IL2RB | Interleukin-2 receptor subunit beta | 0.842 | P06239 | LCK | Tyrosine-protein kinase Lck | P14784 | IL2RB | Interleukin-2 receptor subunit beta | 0.727 | P06239 | LCK | Tyrosine-protein kinase Lck | P13765 | HLA-DOB | HLA class II histocompatibility antigen, DO beta chain | 0.777 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | P13765 | HLA-DOB | HLA class II histocompatibility antigen, DO beta chain | 0.85 | P07305 | H1-0 | Histone H1.0 | P13765 | HLA-DOB | HLA class II histocompatibility antigen, DO beta chain | -0.859 | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | Q13761 | RUNX3 | Runt-related transcription factor 3 | 0.789 | P06239 | LCK | Tyrosine-protein kinase Lck | Q13761 | RUNX3 | Runt-related transcription factor 3 | 0.85 |
| Clozapine | hsa04659 | Th17 cell differentiation | 4.69E-08 | 15 | Q04759, P19174, P01730, P06239, P42224, P14784, P13765, P14778, Q9HBE5, Q9UL17, P23771, P08238, P07766, P09693, P20963 | PRKCQ, PLCG1, CD4, LCK, STAT1, IL2RB, HLA-DOB, IL1R1, IL21R, TBX21, GATA3, HSP90AB1, CD3E, CD3G, CD247 | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
P06239 | LCK | Tyrosine-protein kinase Lck | Q04759 | PRKCQ | Protein kinase C theta type | 0.779 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | Q04759 | PRKCQ | Protein kinase C theta type | 0.803 | P07305 | H1-0 | Histone H1.0 | Q04759 | PRKCQ | Protein kinase C theta type | -0.706 | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | 1 | P06239 | LCK | Tyrosine-protein kinase Lck | P01730 | CD4 | T-cell surface glycoprotein CD4 | 0.746 | P06239 | LCK | Tyrosine-protein kinase Lck | P06239 | LCK | Tyrosine-protein kinase Lck | 1 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | P06239 | LCK | Tyrosine-protein kinase Lck | 0.774 | P07305 | H1-0 | Histone H1.0 | P06239 | LCK | Tyrosine-protein kinase Lck | -0.716 | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | P42224 | STAT1 | Signal transducer and activator of transcription 1-alpha/beta | 0.851 | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | P14784 | IL2RB | Interleukin-2 receptor subunit beta | 0.842 | P06239 | LCK | Tyrosine-protein kinase Lck | P14784 | IL2RB | Interleukin-2 receptor subunit beta | 0.727 | P06239 | LCK | Tyrosine-protein kinase Lck | P13765 | HLA-DOB | HLA class II histocompatibility antigen, DO beta chain | 0.777 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | P13765 | HLA-DOB | HLA class II histocompatibility antigen, DO beta chain | 0.85 | P07305 | H1-0 | Histone H1.0 | P13765 | HLA-DOB | HLA class II histocompatibility antigen, DO beta chain | -0.859 | P06239 | LCK | Tyrosine-protein kinase Lck | P14778 | IL1R1 | Interleukin-1 receptor type 1 | -0.782 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | Q9HBE5 | IL21R | Interleukin-21 receptor | 0.713 | P06239 | LCK | Tyrosine-protein kinase Lck | Q9UL17 | TBX21 | T-box transcription factor TBX21 | 0.866 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | Q9UL17 | TBX21 | T-box transcription factor TBX21 | 0.884 | P06239 | LCK | Tyrosine-protein kinase Lck | P23771 | GATA3 | Trans-acting T-cell-specific transcription factor GATA-3 | 0.77 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | P23771 | GATA3 | Trans-acting T-cell-specific transcription factor GATA-3 | 0.784 | P07305 | H1-0 | Histone H1.0 | P23771 | GATA3 | Trans-acting T-cell-specific transcription factor GATA-3 | -0.772 | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | 0.869 | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | P07766 | CD3E | T-cell surface glycoprotein CD3 epsilon chain | 0.805 | P06239 | LCK | Tyrosine-protein kinase Lck | P07766 | CD3E | T-cell surface glycoprotein CD3 epsilon chain | 0.928 | P06239 | LCK | Tyrosine-protein kinase Lck | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | 0.752 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | 0.813 | P06239 | LCK | Tyrosine-protein kinase Lck | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.927 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.839 |
| Clozapine | hsa04660 | T cell receptor signaling pathway | 1.12E-06 | 13 | P01375, Q9UDY8, Q04759, O95267, Q08881, Q13153, P07766, P20963, P09693, P01730, P01732, Q13191, P06239 | TNF, MALT1, PRKCQ, RASGRP1, ITK, PAK1, CD3E, CD247, CD3G, CD4, CD8A, CBLB, LCK | More | | Clozapine | hsa04668 | TNF signaling pathway | 3.55E-02 | 4 | P01375, P18848, P19875, P14780 | TNF, ATF4, CXCL2, MMP9 | More | | Clozapine | hsa04714 | Thermogenesis | 5.21E-03 | 4 | Q16539, P33121, Q16718, O14521 | MAPK14, ACSL1, NDUFA5, SDHD | More | | Clozapine | hsa04722 | Neurotrophin signaling pathway | 3.27E-02 | 3 | P49841, O43524, P48023 | GSK3B, FOXO3, FASLG | More | | Clozapine | hsa04740 | Olfactory transduction | 2.52E-02 | 1 | Q9H255 | OR51E2 | More | | Clozapine | hsa04742 | Taste transduction | 1.01E-02 | 1 | P30939 | HTR1F | More | | Clozapine | hsa04744 | Phototransduction | 8.50E-03 | 2 | P62873, P0DP23 | GNB1, CALM1 | More | | Clozapine | hsa04913 | Ovarian steroidogenesis | 2.54E-02 | 2 | P42330, P22694 | AKR1C3, PRKACB | More | | Clozapine | hsa04919 | Thyroid hormone signaling pathway | 2.48E-02 | 5 | P19174, P42224, P60709, Q13547, P01106 | PLCG1, STAT1, ACTB, HDAC1, MYC | More | | Clozapine | hsa04924 | Renin secretion | 4.04E-02 | 2 | P22694, P07550 | PRKACB, ADRB2 | More | | Clozapine | hsa04926 | Relaxin signaling pathway | 2.41E-02 | 4 | P18848, P22694, P14780, P30679 | ATF4, PRKACB, MMP9, GNA15 | More | | Clozapine | hsa04927 | Cortisol synthesis and secretion | 2.54E-02 | 2 | P18848, P22694 | ATF4, PRKACB | More | | Clozapine | hsa04932 | Non-alcoholic fatty liver disease | 2.44E-03 | 5 | P01375, P49841, P48023, Q16718, O14521 | TNF, GSK3B, FASLG, NDUFA5, SDHD | More | | Clozapine | hsa04940 | Type I diabetes mellitus | 1.87E-02 | 2 | P48023, P01375 | FASLG, TNF | More | | Clozapine | hsa04970 | Salivary secretion | 1.91E-02 | 3 | P07550, P22694, P49913 | ADRB2, PRKACB, CAMP | More | | Clozapine | hsa04976 | Bile secretion | 3.32E-02 | 2 | O43315, P08183 | AQP9, ABCB1 | More | | Clozapine | hsa05017 | Spinocerebellar ataxia | 2.43E-02 | 1 | P28074 | PSMB5 | More | | Clozapine | hsa05020 | Prion disease | 3.80E-02 | 4 | Q16718, O14521, P49841, Q16539 | NDUFA5, SDHD, GSK3B, MAPK14 | More | | Clozapine | hsa05022 | Pathways of neurodegeneration - multiple diseases | 1.24E-02 | 6 | P49841, Q16718, O14521, Q13561, Q16539, Q08752 | GSK3B, NDUFA5, SDHD, DCTN2, MAPK14, PPID | More | | Clozapine | hsa05031 | Amphetamine addiction | 4.32E-02 | 3 | P22694, P18848, Q13547 | PRKACB, ATF4, HDAC1 | More | | Clozapine | hsa05032 | Morphine addiction | 1.90E-02 | 4 | P62873, P63218, Q13370, P43250 | GNB1, GNG5, PDE3B, GRK6 | More | | Clozapine | hsa05034 | Alcoholism | 1.76E-05 | 8 | Q13547, P0DP23, P62873, P63218, Q93077, P62807, O60814, P68431 | HDAC1, CALM1, GNB1, GNG5, HIST1H2AC, HIST1H2BC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | | Clozapine | hsa05120 | Epithelial cell signaling in Helicobacter pylori infection | 3.10E-03 | 5 | Q16539, Q13153, P09341, P25024, P25025 | MAPK14, PAK1, CXCL1, CXCR1, CXCR2 | More | | Clozapine | hsa05134 | Legionellosis | 4.28E-02 | 3 | P11215, P11142, P19875 | ITGAM, HSPA8, CXCL2 | More | | Clozapine | hsa05140 | Leishmaniasis | 2.26E-04 | 8 | P13612, O75015, P13765, O60603, P01375, P49006, Q16539, Q15080 | ITGA4, FCGR3B, HLA-DOB, TLR2, TNF, MARCKSL1, MAPK14, NCF4 | More | | Clozapine | hsa05143 | African trypanosomiasis | 2.72E-02 | 2 | P01375, P48023 | TNF, FASLG | More | | Clozapine | hsa05144 | Malaria | 6.75E-04 | 5 | P60033, O60603, P01375, P35443, P26718 | CD81, TLR2, TNF, THBS4, KLRK1 | More | | Clozapine | hsa05146 | Amoebiasis | 7.98E-06 | 11 | P09341, P19875, P14778, P27930, P01375, O60603, P05089, P30679, P22694, P12814, P08311 | CXCL1, CXCL2, IL1R1, IL1R2, TNF, TLR2, ARG1, GNA15, PRKACB, ACTN1, CTSG | More | | Clozapine | hsa05160 | Hepatitis C | 1.27E-02 | 4 | P60033, P49841, P01375, P48023 | CD81, GSK3B, TNF, FASLG | More | | Clozapine | hsa05163 | Human cytomegalovirus infection | 3.64E-02 | 7 | Q14643, P49841, P14778, P25025, Q16539, P04637, O00463 | ITPR1, GSK3B, IL1R1, CXCR2, MAPK14, TP53, TRAF5 | More | | Clozapine | hsa05165 | Human papillomavirus infection | 2.26E-02 | 6 | Q16363, P30281, Q9UM47, P01889, P10321, Q99437 | LAMA4, CCND3, NOTCH3, HLA-B, HLA-C, ATP6V0B | More | | Clozapine | hsa05167 | Kaposi sarcoma-associated herpesvirus infection | 8.64E-03 | 7 | P42224, P62873, P63218, P19875, P19174, P01106, P0DP23 | STAT1, GNB1, GNG5, CXCL2, PLCG1, MYC, CALM1 | More | | Clozapine | hsa05169 | Epstein-Barr virus infection | 5.82E-04 | 13 | P13765, P01106, Q13547, O00463, P07948, P30101, Q13761, P24522, O75293, P42224, P07766, P09693, P20963 | HLA-DOB, MYC, HDAC1, TRAF5, LYN, PDIA3, RUNX3, GADD45A, GADD45B, STAT1, CD3E, CD3G, CD247 | More | | Clozapine | hsa05171 | Coronavirus disease - COVID-19 | 3.03E-05 | 11 | P23396, P62249, P42677, P40429, Q02878, P62917, P27635, P26373, Q07020, P46776, P05386 | RPS3, RPS16, RPS27, RPL13A, RPL6, RPL8, RPL10, RPL13, RPL18, RPL27A, RPLP1 | More | | Clozapine | hsa05200 | Pathways in cancer | 2.60E-02 | 12 | P08238, P42224, P19174, P01106, P43246, P20585, Q13547, P62873, P63218, O75293, P0DP23, P14784 | HSP90AB1, STAT1, PLCG1, MYC, MSH2, MSH3, HDAC1, GNB1, GNG5, GADD45B, CALM1, IL2RB | More | | Clozapine | hsa05202 | Transcriptional misregulation in cancer | 2.35E-02 | 12 | Q13315, P14780, P27930, Q15744, Q16548, Q13077, P35226, P05164, P12838, P08246, Q9C0K0, P24522 | ATM, MMP9, IL1R2, CEBPE, BCL2A1, TRAF1, BMI1, MPO, DEFA4, ELA2, BCL11B, GADD45A | More | | Clozapine | hsa05203 | Viral carcinogenesis | 6.28E-04 | 11 | P06746, P30281, P29083, Q13547, Q15283, P06396, P12814, P01889, P10321, P62807, O60814 | POLB, CCND3, GTF2E1, HDAC1, RASA2, GSN, ACTN1, HLA-B, HLA-C, HIST1H2BC, H2BC12 | More | | Clozapine | hsa05204 | Chemical carcinogenesis | 1.09E-03 | 3 | P09211, P78417, P11712 | GSTP1, GSTO1, CYP2C9 | More | | Clozapine | hsa05205 | Proteoglycans in cancer | 3.68E-02 | 5 | P14780, P01375, P23588, Q13635, P22694 | MMP9, TNF, EIF4B, PTCH1, PRKACB | More | | Clozapine | hsa05206 | MicroRNAs in cancer | 3.17E-02 | 6 | P30304, P09493, P01106, Q9Y4H2, Q13547, P19174 | CDC25A, TPM1, MYC, IRS2, HDAC1, PLCG1 | More | | Clozapine | hsa05211 | Renal cell carcinoma | 2.42E-02 | 1 | Q13153 | PAK1 | More | | Clozapine | hsa05214 | Glioma | 4.28E-02 | 3 | P0DP23, P19174, O75293 | CALM1, PLCG1, GADD45B | More | | Clozapine | hsa05219 | Bladder cancer | 2.70E-03 | 2 | P14780, P04637 | MMP9, TP53 | More | | Clozapine | hsa05224 | Breast cancer | 5.68E-03 | 4 | P49841, Q92837, P04637, P24522 | GSK3B, FRAT1, TP53, GADD45A | More | | Clozapine | hsa05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 1.32E-03 | 9 | O95267, P07766, P20963, P09693, P06239, O60603, Q04759, Q16539, P01730 | RASGRP1, CD3E, CD247, CD3G, LCK, TLR2, PRKCQ, MAPK14, CD4 | More | | Clozapine | hsa05310 | Asthma | 1.03E-03 | 3 | P13765, P12724, P01375 | HLA-DOB, RNASE3, TNF | More | | Clozapine | hsa05321 | Inflammatory bowel disease | 1.17E-05 | 7 | O60603, P01375, P13765, Q14765, Q9UL17, P23771, Q9HBE5 | TLR2, TNF, HLA-DOB, STAT4, TBX21, GATA3, IL21R | More | | Clozapine | hsa05322 | Systemic lupus erythematosus | 8.24E-05 | 6 | P09871, Q93077, P62807, O60814, P68431, P12814 | C1S, HIST1H2AC, HIST1H2BC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12, ACTN1 | More | | Clozapine | hsa05330 | Allograft rejection | 2.72E-02 | 2 | P48023, P01375 | FASLG, TNF | More | | Clozapine | hsa05332 | Graft-versus-host disease | 7.43E-06 | 5 | P13765, P48023, P01375, P26715, Q13241 | HLA-DOB, FASLG, TNF, KLRC1, KLRD1 | More | | Clozapine | hsa05340 | Primary immunodeficiency | 2.19E-02 | 4 | P01730, P01732, P07766, P06239 | CD4, CD8A, CD3E, LCK | More | | Clozapine | hsa05415 | Diabetic cardiomyopathy | 1.28E-02 | 4 | Q16718, O14521, Q16539, P49841 | NDUFA5, SDHD, MAPK14, GSK3B | More | | Clozapine | hsa05418 | Fluid shear stress and atherosclerosis | 2.62E-02 | 6 | Q16539, P10599, P14780, P04637, P14778, P27930 | MAPK14, TXN, MMP9, TP53, IL1R1, IL1R2 | More | | |